Clinical Trials Directory

Trials / Completed

CompletedNCT03706235

Colvera for Detection of Disease Recurrence

Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed With Colorectal Cancer- "NOVA"

Status
Completed
Phase
Study type
Observational
Enrollment
488 (actual)
Sponsor
Clinical Genomics Pathology · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.

Detailed description

This is an observational, prospective comparison study, where blood is collected for assay of methylated BCAT1 and IKZF1 DNA and CEA, from subjects who have undergone curative treatment for primary CRC of stages II and III (AJCC) and who are in remission and scheduled for follow-up radiological imaging as part of their surveillance program for recurrence. Participation is for one visit only as part of each subject's surveillance-monitoring schedule. Two K2-EDTA blood tubes and two PAXgene™ tubes will be collected Any evidence of methylated BCAT1 and/or IKZF1 DNA in blood represents a Colvera "positive" result. CEA levels of 5ug/L or higher will represent a "positive" result. Sensitivity and specificity of the Colvera and CEA test will be estimated and compared in a paired fashion in each case where recurrence status has been investigated and determined by the site clinical management team. Blood testing shall be performed and analyzed by qualified staff blinded to clinical status. This is a cross-sectional observational non-significant risk study, and test results will not be used for clinical management, i.e. there will be no interventions in subjects consenting to participate in this Research Study.

Conditions

Interventions

TypeNameDescription
OTHERBlood draw (venipuncture)Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.

Timeline

Start date
2018-02-01
Primary completion
2019-08-16
Completion
2020-04-29
First posted
2018-10-15
Last updated
2020-07-14

Locations

12 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03706235. Inclusion in this directory is not an endorsement.